Table 3.

Prognostic factors of overall survival, disease free survival and local control among the 48 extramedullary plasmacytoma patients

Variable	Overall survival			Disease free survival
	P	Relative risk	95 % CI	P	Relative risk	95 % CI
I
Gender (Male vs Female)	0.382	2.287	0.358–14.613	0.940	0.953	0.276–3.297
Age, years (<50 vs ≧ 50)	0.375	2.282	0.369–14.112	0.752	1.216	0.362–4.085
Lymph node metastasis (Without vs With)	0.019	10.335	1.463–72.986	0.048	4.279	1.014–18.052
Size of primary tumor (<5 cm vs ≧5 cm)	0.026	18.612	1.416–244.713	0.004	7.496	1.903–29.534
Number of primary tumors (Solitary vs Sporadic)	0.480	2.223	0.242–20.455	0.723	0.770	0.182–5.074
Treatment (Single vs Combined)	0.650	0.728	0.185–2.872	0.910	0.940	0.321–2.754
Anatomic Location (HN vs Others)	0.306	2.096	0.508–8.647	0.988	1.008	0.356–2.856
II
Gender (Male vs Female)	0.378	2.276	0.364–14.230	0.990	1.008	0. 300–3.388
Age, years (<50 vs ≧ 50)	0.411	2. 049	0.371–11.311	0.807	1.159	0.354–3.799
Clinical stage (I vs II vs III)	0.001	13.030	2.812–60.382	<0.001	5. 795	2.245–14.958
Number of primary tumors (Solitary vs Sporadic)	0.472	2.248	0.247–20.461	0.746	0.791	0.191–3.272
Treatment (Single vs Combined)	0.680	0.680	0.190–2.957	0.982	0.988	0.342–2.851
Anatomic location (HN vs Others)	0.291	2.291	0.521–8.842	0.951	1.033	0.365–2.924

Abbreviation: HN head and neck